Contact lens maker Bausch + Lomb says it is exploring sale

Bausch + Lomb is considering a sale to aid parent Bausch Health's exit, amid private equity interest, following share volatility and earlier reports of a potential bid.

Bausch + Lomb stock extends gains as Jefferies describes it as an 'undervalued asset'

Jefferies values Bausch + Lomb at $25 per share, citing high potential returns and a possible sale beneficial for stakeholders amid ongoing acquisition speculation.

Bausch + Lomb explores potential sale amid market rumors

Bausch + Lomb is exploring a potential sale amid stock volatility, while refraining from disclosing further details until necessary, impacting the eye care industry and investor interest.

Canada stocks higher at close of trade; S&P/TSX Composite up 0.60%